These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19434781)

  • 1. Emerging multiple sclerosis disease-modifying therapies.
    Giacomini PS; Darlington PJ; Bar-Or A
    Curr Opin Neurol; 2009 Jun; 22(3):226-32. PubMed ID: 19434781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC; Meuth SG; Bittner S; Kleinschnitz C; Kieseier BC; Wiendl H
    BioDrugs; 2010 Aug; 24(4):249-74. PubMed ID: 20623991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New and emerging disease modifying therapies for multiple sclerosis.
    Saidha S; Eckstein C; Calabresi PA
    Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
    Menge T; Weber MS; Hemmer B; Kieseier BC; von Büdingen HC; Warnke C; Zamvil SS; Boster A; Khan O; Hartung HP; Stüve O
    Drugs; 2008; 68(17):2445-68. PubMed ID: 19016573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
    Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
    J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.
    Du Pasquier RA; Pinschewer DD; Merkler D
    CNS Drugs; 2014 Jun; 28(6):535-58. PubMed ID: 24723124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials in multiple sclerosis: methodological issues.
    Comi G; Filippi M
    Curr Opin Neurol; 2005 Jun; 18(3):245-52. PubMed ID: 15891407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].
    Kleinschnitz C; Meuth SG; Kieseier BC; Wiendl H
    Nervenarzt; 2007 Aug; 78(8):883-911. PubMed ID: 17551708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of multiple sclerosis treatment.
    Cohen JA
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory drug treatment in multiple sclerosis.
    Aharoni R
    Expert Rev Neurother; 2010 Sep; 10(9):1423-36. PubMed ID: 20819013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenetic treatment of multiple sclerosis: the present and the future].
    Boĭko AN; Stoliarov ID; Sidorenko TV; Kulakova OV; Kol'iak EV; Petrov AM; Il'ves AG; Nikiforova IG; Favorova OO; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):90-9. PubMed ID: 19894313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis research: diagnostics, disease-modifying treatments, and emerging therapies.
    Costello K
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S14-23. PubMed ID: 24217187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
    Komoly S
    Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing Risks with Immune Therapies in Multiple Sclerosis.
    Förster M; Küry P; Aktas O; Warnke C; Havla J; Hohlfeld R; Mares J; Hartung HP; Kremer D
    Drug Saf; 2019 May; 42(5):633-647. PubMed ID: 30607830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.